Sign In
Buy NDAQ
$82.49
-0.120 (-0.145%)
At Close: Jun 23, 2026
Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Friday, 11'th Apr 2025
BEDFORD, Mass., April 11, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a biopharmaceutical company committed to redefining the retina experience, today announced tha
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Friday, 11'th Apr 2025
CAMBRIDGE, Mass., April 11, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives
Polyrizon Receives Nasdaq Notification Regarding Minimum Bid Requirements
04:15pm, Friday, 11'th Apr 2025
Raanana, Israel, April 11, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development stage biotech company specializing in the development of innovat
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Friday, 11'th Apr 2025
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on April 3, 2025, the Compensation Committee of Acadia's Board of Directors (the “Committee”) granted in
4DMT Announces New Employment Inducement Grants
04:05pm, Friday, 11'th Apr 2025
EMERYVILLE, Calif., April 11, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
04:01pm, Friday, 11'th Apr 2025
PALO ALTO, Calif., April 11, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic dise
Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:01pm, Friday, 11'th Apr 2025
SAN FRANCISCO, April 11, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of tar
Nasdaq Gains Over 50 Points; JPMorgan Posts Upbeat Earnings
10:14am, Friday, 11'th Apr 2025
U.S. stocks traded higher this morning, with the Nasdaq Composite gaining more than 50 points on Friday.
Nasdaq Bear Market: Could Buying Nvidia Today Set You Up for Life?
10:00am, Friday, 11'th Apr 2025
With the Nasdaq Composite in bear market territory, many stocks look like absolute bargains compared to their previous values. One of those stocks is Nvidia (NVDA 2.65%), which has been practically th
Dogwood Therapeutics, Inc. Receives Nasdaq Confirmation of Compliance
09:15am, Friday, 11'th Apr 2025
ATLANTA, April 11, 2025 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), a development-stage biopharmaceutical company focused on developing new medicines to treat pa
PetMeds® to Ring Nasdaq Opening Bell in Celebration of National Pet Day on April 11th
09:00am, Friday, 11'th Apr 2025
DELRAY BEACH, Fla., April 11, 2025 (GLOBE NEWSWIRE) -- In celebration of National Pet Day, PetMed Express, Inc. (NASDAQ: PETS)—the original consumer pet healthcare company serving dogs, cats, and ho
Blink Charging Co. Regains Compliance with Nasdaq Periodic Filing Requirement
09:00am, Friday, 11'th Apr 2025
Bowie, MD., April 11, 2025 (GLOBE NEWSWIRE) -- Blink Charging Co. (Nasdaq: BLNK) (“Blink” or the “Company”), a leading global owner, operator, provider, and manufacturer of electric vehicle
Venus Concept Announces $1.5 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
08:02am, Friday, 11'th Apr 2025
TORONTO, April 11, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced that it has ente
Nasdaq Bear Market: Should You Buy ASML Stock Right Now?
08:00am, Friday, 11'th Apr 2025
ASML (ASML -5.42%) navigates a worldwide supplier and distribution network, making it vulnerable to increasing trade barriers.
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08:00am, Friday, 11'th Apr 2025
BRISBANE, Calif., April 11, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies, today announced the granting
